Donor Cell–Derived Leukemias/Myelodysplastic Neoplasms in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Endi Wang(University of Southern California), Patrick J. Buckley(Duke Medical Center), Mitchell E. Horwitz(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Frances F. Wang(Duke Medical Center), Charles Blake Hutchinson(Duke University), Qin Huang(People's Hospital of Xinjiang Uygur Autonomous Region), Chuanyi M. Lu(San Francisco VA Health Care System), David A. Rizzieri(Duke University), Michael Datto(Duke University), Barbara K. Goodman(Duke Medical Center), Jennifer Crow(Duke Medical Center), Anand S. Lagoo(Duke Medical Center), Jingwei Yu, Siby Sebastian(Duke University), Catherine Rehder(Duke University)
American Journal of Clinical Pathology
March 16, 2011
10.1309/ajcppjuq9dnr1ghp
Cited by 64

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
|Blood|2018|457
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
|Journal of Clinical Oncology|2013|439